Table 2 Enriched pathways and the involved target genes of the studied miRNAs in each pathway
From: Epigenetic effects toward new insights as potential therapeutic target in B-thalassemia
Pathway | Target genes of the studied microRNAs involved in that pathway | |
|---|---|---|
Predicted | Validated | |
Insulin signaling pathway | AKT2, BRAF, KRAS, SOS1, PDPK1, CALM1, ERS2, INSR, MAPK1, MAPK3, MAPK8, MAPK9, MAPK10, NRAS, PIK3R1, PIK3R2, PIK3R3, PRKAA1, PRKAA2, PRKAB2, RPS6KB1 | AKT3, KRAS, FOXO1 |
MAPK signaling pathway | AKT2, BRAF, KRAS, SOS1, EGFR, MAPK1, MAPK3, MAPK8, MAPK9, MAPK10, MAP2K4, NRAS, TGFBR1, TGFBR2 | AKT3, KRAS, RPS6KA3 |
Neurotrophin signaling pathway | PDPK1, ABL1, AKT2, BRAF, KRAS, SOS1, CALM1, BCL2, FOXO3, PIK3R1, MAPK1, MAPK3, MAPK8, MAPK9, MAPK10, NRAS, PIK3R1, PIK3R2, PIK3R3, | AKT3, KRAS, BCL2, FOXO3, RPS6KA3 |
Chronic myeloid leukemia | ABL1, AKT2, E2F1, E2F2, E2F3, BRAF, KRAS, MDM2, SMAD4, SOS1, CCND1, CDK6, MAPK1, MAPK3, NRAS, PIK3R1, PIK3R2, PIK3R3, RUNX1, STAT5B, TGFBR1, TGFBR2 | AKT3, KRAS, CCND1 |
Ras signaling pathway | ABL1, AKT2, KRAS, SOS1, CALM1, IGF1R, EGFR, INSR, MAPK1, MAPK3, MAPK8, MAPK9, MAPK10, NRAS, PIK3R1, PIK3R2, PIK3R3 | AKT3, KRAS |
FOXO signaling pathway | PDPK1, AKT2, BRAF, KRAS, SOS1, BC2L11, GABARAPL1, MDM2, SMAD2, SMAD3, SMAD4, CCND1, CCND2, EGFR, FOXO1, FOXO3, IGF1R, IRS2, INSR, IL7R, MAPK1, MAPK3, MAPK8, MAPK9, MAPK10, NRAS, PIK3R1, PIK3R2, PIK3R3, PRKAA1, PRKAA2, PRKAB2, SGK1, TGFBR1, TGFBR2 | AKT3, KRAS, CCND1, CCND2 |
GnRH signaling pathway | KRAS, SOS1, CALM1, EGFR, MAPK1, MAPK3, MAPK8, MAPK9, MAPK10, MAP2K4, NRAS | KRAS |